Seattle Genetics gains on brentuximab data

Seattle Genetics Inc. (NASDAQ:SGEN) gained $2.14 (18%) to $14.30 on Monday after it and partner Millennium Pharmaceuticals Inc. reported data from a pivotal Phase II trial of brentuximab vedotin to treat relapsed or refractory Hodgkin's lymphoma. Brentuximab produced an overall response rate of 75%, with a median duration of response of more than six months. Based on the results, Seattle Genetics plans to submit a BLA to FDA in 1H11 seeking accelerated approval for brentuximab. The company also plans to submit an MAA in Europe next year. The single-arm, international trial enrolled 102 patients who previously received an autologous stem cell transplant. ...